Related Experiment Video
Updated: Jun 30, 2026
Preliminary Study on Acupuncture Combined with Grain-sized Moxibustion for Treating Rheumatoid Arthritis with Finger Joint Pain
Published on: May 16, 2025
New therapeutic approaches for rheumatoid arthritis
1Key Laboratory of Bio-Process, HeFei University of Technology, Ministry of Education--People's Republic of China, Hefei, People's Republic of China. chenq2008@mail.xbzh.com
Abstract:
Rheumatoid arthritis (RA) is a chronic polyarthritis leading to joint destruction and remarkable disability. Current therapies have various degrees of efficacy, but toxicity frequently limits their long-term use. Although the etiology of the disease remains unknown, our increasing knowledge of the mechanisms underlying pathogenic events in rheumatoid synovitis has enabled selective targeting of the pathogenic elements of disease. Several new drugs have recently been introduced for the treatment of RA. These include cyclooxygenase type 2 inhibitors, adhesion molecules, T cells, B cells, cytokine/receptor, chemokines, angiogenesis, oral tolerance antigens, costimulatory molecules, and new disease-modifying antirheumatic drugs. Continuing research into the pathogenesis of RA will undoubtedly identify even more effective therapeutic approaches for the management of this disease in the future. In conclusion, the proof of principle has been established that selective targeting of pathogenic elements of disease results in substantial improvement in signs and symptoms as well as disease progression. Improved efficacy is expected with more aggressive targeting of the pathogenic elements.
Insights
Targeting specific disease mechanisms in rheumatoid arthritis (RA) offers improved treatment efficacy. New therapies selectively target pathogenic elements, showing promise for managing joint destruction and disability associated with RA.
Area of Science:
- Rheumatology
- Immunology
- Pharmacology
Background:
- Rheumatoid arthritis (RA) is a chronic inflammatory disease causing joint destruction and disability.
- Current RA therapies have limited long-term efficacy due to toxicity.
- Understanding RA pathogenesis enables targeted therapeutic strategies.
Purpose of the Study:
- To review emerging therapeutic approaches for rheumatoid arthritis.
- To highlight the benefits of selectively targeting pathogenic elements in RA treatment.
Main Methods:
- Review of recent advancements in RA drug development.
- Analysis of novel therapeutic targets including cyclooxygenase type 2 inhibitors, adhesion molecules, T cells, B cells, cytokine/receptor interactions, chemokines, angiogenesis, oral tolerance antigens, and costimulatory molecules.
- Evaluation of new disease-modifying antirheumatic drugs (DMARDs).
Main Results:
- Selective targeting of pathogenic elements in RA has demonstrated significant improvements in clinical signs, symptoms, and disease progression.
- New drug classes show promise in managing RA more effectively.
- The proof of principle for targeted therapy in RA is established.
Conclusions:
- Targeted therapies represent a significant advancement in rheumatoid arthritis management.
- Further research into RA pathogenesis will yield even more effective treatments.
- Selective targeting of disease mechanisms offers substantial benefits for RA patients.
Related Concept Videos
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
01:29Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
01:24Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
01:29Inflammatory Bowel Disease IV: Pharmacological Management
Pharmacologic...
01:21Rheumatic Heart Disease III: Medical Management
01:20Rheumatic Heart Disease IV: Nursing Management